WO2003048185A3 - Angiopioetin related factors - Google Patents
Angiopioetin related factors Download PDFInfo
- Publication number
- WO2003048185A3 WO2003048185A3 PCT/US2002/037660 US0237660W WO03048185A3 WO 2003048185 A3 WO2003048185 A3 WO 2003048185A3 US 0237660 W US0237660 W US 0237660W WO 03048185 A3 WO03048185 A3 WO 03048185A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- wild
- domain
- amino acid
- acid sequence
- fusion proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002359464A AU2002359464A1 (en) | 2001-11-30 | 2002-11-21 | Angiopioetin related factors |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33448801P | 2001-11-30 | 2001-11-30 | |
| US60/334,488 | 2001-11-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2003048185A2 WO2003048185A2 (en) | 2003-06-12 |
| WO2003048185A3 true WO2003048185A3 (en) | 2004-06-24 |
Family
ID=23307442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2002/037660 Ceased WO2003048185A2 (en) | 2001-11-30 | 2002-11-21 | Angiopioetin related factors |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002359464A1 (en) |
| WO (1) | WO2003048185A2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7081443B2 (en) | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
| LT1781698T (en) | 2004-07-20 | 2016-09-26 | Genentech, Inc. | Compositions and methods of using angiopoietin-like 4 protein |
| WO2006014729A2 (en) | 2004-07-20 | 2006-02-09 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| CA2581769C (en) * | 2004-09-28 | 2014-03-11 | Genexel-Sein, Inc. | Methods of using chimeric coiled-coil molecule |
| EP2446897A1 (en) | 2005-01-06 | 2012-05-02 | Novo Nordisk A/S | Anti-KIR combination treatments and methods |
| EA015584B1 (en) | 2005-03-23 | 2011-10-31 | Генмаб А/С | ANTIBODY TO CD38 PERSON AND ITS APPLICATION |
| SG195082A1 (en) | 2011-05-25 | 2013-12-30 | Innate Pharma Sa | Anti-kir antibodies for the treatment of inflammatory disorders |
| WO2013154744A1 (en) * | 2012-04-13 | 2013-10-17 | Cornell University | Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction |
| US9540428B2 (en) * | 2012-07-03 | 2017-01-10 | Ecole Polytechnique Federale De Lausanne (Epfl) | Extracellular matrix heparin-binding domains |
| GB202108761D0 (en) * | 2021-06-18 | 2021-08-04 | Ikarovec Ltd | Ocular disorders |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074873A (en) * | 1997-09-19 | 2000-06-13 | Genentech, Inc. | Nucleic acids encoding NL-3 |
| US6265564B1 (en) * | 1996-08-02 | 2001-07-24 | Regeneron Pharmaceuticals, Inc. | Expressed ligand-vascular intercellular signalling molecule |
| US6406693B1 (en) * | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
-
2002
- 2002-11-21 WO PCT/US2002/037660 patent/WO2003048185A2/en not_active Ceased
- 2002-11-21 AU AU2002359464A patent/AU2002359464A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6265564B1 (en) * | 1996-08-02 | 2001-07-24 | Regeneron Pharmaceuticals, Inc. | Expressed ligand-vascular intercellular signalling molecule |
| US20030092891A1 (en) * | 1996-08-02 | 2003-05-15 | Samuel Davis | Expressed ligand - vascular intercellular signalling molecule |
| US6074873A (en) * | 1997-09-19 | 2000-06-13 | Genentech, Inc. | Nucleic acids encoding NL-3 |
| US6406693B1 (en) * | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002359464A8 (en) | 2003-06-17 |
| WO2003048185A2 (en) | 2003-06-12 |
| AU2002359464A1 (en) | 2003-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003048185A3 (en) | Angiopioetin related factors | |
| WO2002059306A3 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
| WO2002095049A3 (en) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof | |
| WO2003006671A3 (en) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof | |
| WO2002040683A3 (en) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof | |
| WO2003048303A3 (en) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof | |
| WO2001088148A3 (en) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof | |
| WO2002077190A8 (en) | Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof | |
| WO2003006485A3 (en) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof | |
| WO2002072831A3 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
| WO2003006483A3 (en) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof | |
| WO2002074976A3 (en) | Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof | |
| WO2002079407A8 (en) | Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof | |
| WO2003001880A3 (en) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof | |
| WO2002059288A3 (en) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof | |
| WO2002079431A3 (en) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof | |
| WO2002061062A3 (en) | Human protein kinase n-like polypeptide and uses thereof | |
| WO2002059317A3 (en) | Cub domain protein zcub3 and materials and methods for making it | |
| WO2002068468A3 (en) | Isolated human tumor supressor proteins, nucleic acid molecules encoding these human tumor supressor proteins, and uses thereof | |
| WO2002079225A3 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
| WO2002079227A3 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
| WO2002083900A3 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
| WO2001090360A3 (en) | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof | |
| WO2003006484A3 (en) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof | |
| WO2002101080A3 (en) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |